Skip to contentP
Protagenic Therapeutics, Inc.\new
P
PTIXProtagenic Therapeutics, Inc.\new Q1 2023 · 10-Q
Revenue$0.00$0.00— vs Q1 2022 Net Income-$718.10K-$718.10KN/M vs Q1 2022 EPS Diluted-$0.17-$0.17no prior Q1 2022 on file Operating Income-$739,294N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end